Bristol Myers Squibb is led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases.
We’re committed to the UK. In 2020, our total economic footprint in the UK economy was an estimated £1bn in gross value added (GVA) and we supported 13,200 full time equivalent (FTE) jobs across the country1, with 95% of our procurement supplied from British businesses2.
Each day, the 1,200 people we directly employ in the UK work together for patients - it drives everything we do. In 2020, ~800,000 patients in the UK & Ireland relied on our medicines3. We are focused on helping millions of patients around the world in disease areas such as oncology, haematology, cardiology, immunology, fibrosis, and specialty medicines. We have built a sustainable pipeline through our Research & Development organisation, which invested £68 million in the UK in 2020. We seek out external partners to drive innovation and broaden and accelerate our work.
As global citizens, we work sustainably and responsibly and seek to give back. For example, in 2020, we donated £2 million to NHS cancer services, charities and patient groups to support NHS cancer services during the pandemic4.
Through the Bristol Myers Squibb Foundation, we promote health equity and strive to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.
